Draft:Sean D. Sullivan
 | Draft article not currently submitted for review.
This is a draft Articles for creation (AfC) submission. It is not currently pending review. While there are no deadlines, abandoned drafts may be deleted after six months. To edit the draft click on the "Edit" tab at the top of the window. To be accepted, a draft should:
It is strongly discouraged to write about yourself, your business or employer. If you do so, you must declare it. Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
Last edited by Mbounthavong (talk | contribs) 10 days ago. (Update) |
Sean D. Sullivan | |
|---|---|
| Born | September 30, 1960 San Jose, CA, USA |
| Citizenship | United States of America |
| Academic career | |
| Field | health economics |
| Institution | University of Washington |
| Alma mater | University of California Berkeley (Ph.D.) University of Texas, Austin (MSc.) Oregon State University College of Pharmacy (BSc.Pharm.) |
| Doctoral advisor | Teh-wei Hu |
| Doctoral students | Mitch Higashi, Kai Yeung, Jonathan H. Watanabe |
| Influences | Pharmacoeconomics, health economics |
| Website | sop |
Sean D. Sullivan (born 1960) is an American health economist, professor, Member of the National Academies of Sciences, Engineering, and Medicine,[1],[2] and Fellow of the American Association for the Advancement of Science (AAAS)[3] who has made significant contributions to pharmacoeconomics, health technology assessment, decision sciences, drug pricing, value-based insurance design, and health coverage and reimbursement decisions. Sullivan was the past dean of the University of Washington School of Pharmacy and past president of the ISPOR-The Professional Society for Health Economics and Outcomes Research. Sullivan has been recognized with numerous awards included the Steven G. Avey Award from the Academy of Managed Care Pharmacy and the David Almquist Award from the Washington State Pharmacy Association. Sullivan has published over 400 articles, book chapters, task force reports, and governmental publications.
Education
Sullivan received his Bachelors of Pharmacy from Oregon State University, College of Pharmacy in 1983, Masters of Science from the University of Texas, Austin in 1986, and his Doctor of Philosophy from the University of California Berkeley in 1992. During his doctoral training, Sullivan was advised by Teh-wei Hu, a prominent health economist at the University of California Berkeley.
Career
During his doctoral training, Sullivan was an Affiliate Assistant Professor at the College of Professional Studies, University of California San Francisco and Visiting Instructor at the School of Pharmacy, University of the Pacific. After his doctoral training, Sullivan took a position as Assistant Professor at the Schools of Pharmacy and Public Health/Community Medicine, University of Washington eventually reaching the rank of Full Professor. Sullivan was the past Stergachis Family Endowed Professor and Director of The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute (1997-2014), Associate Dean of Research, Graduate Education and New Initiatives at University of Washington School of Pharmacy (2011-2014), and Dean and Chief Academic Officer at University of Washington School of Pharmacy (2014-2022). Sullivan is currently Full Professor at University of Washington School of Pharmacy and University of Washington School of Public Health, and Visiting Professor at London School of Economics and Political Science (2022-2026).
AMCP Dossier
The Academy of Managed Care Pharmacy (AMCP) Dossier, a comprehensive document containing information about the effectiveness, safety, and economic impact of a pharmaceutical agent, is used by healthcare decision-makers to inform them on policies associated with formulary coverage and price negotiation.[4] Sullivan was instrumental in its development along with Paul C. Langley from Latrobe University. Drawing inspiration from the Australian guidelines for informing drug coverage by the Pharmaceutical Benefits Advisory Committee (PBAC), they developed the framework for managed care organizations to standardize their decision-making process to incorporate clinical and economic outcomes, which included product description, place in therapy, comparator products, therapy intervention framework, supporting clinical data, supporting pharmacoeconomic data, system impact assessments-costs-outcomes, overall assessment.[5] This led to the first AMCP Dossier Format version 1.0, which was publised in October 2000.[6],[7] Since it's inception, the AMCP Dossier for Formulary Submissions has been widely used by managed care organizations and formulary managers to inform them on healthcare decisions regarding formulary coverage and price negoations. In recognition of his contributions, Sullivan was elected to the National Academy of Medicine in 2020.[8]
Value-Based Formulary
Value-based formulary design (VBID) leverages health technology assessment or cost-effectiveness analysis to identify high-value pharmaceutical interventions that healthcare insurers are willing to pay or provide to their beneficiaries.[9] Sullivan and colleagues were one of the first to evaluate the effectiveness of value-based formulary design on large healthcare systems.[10],[11],[12] Their findings indicate that value-based formulary design can decrease costs while maintaiing the quality of healthcare delivered by health care plans.
Medicare Price Negotiation
In 2022, President Biden signed into law the Inflation Reduction Act (Public Law 117-169), which gave the Medicare (United States) the ability to directy negotiate with pharmaceutical manufactures for some of the costliest drugs on the Part B and D plans.
References
- ^ "UWSOP Dean Sean D. Sullivan Elected To NAM". University of Washington. 19 October 2020. Retrieved 26 August 2024.
- ^ "National Academy of Medicine Elects 100 New Members". National Academy of Medicine. 19 October 2020. Retrieved 27 August 2024.
- ^ "Sullivan Named 2022 AAAS Fellow". University of Washington. 3 February 2024. Retrieved 26 August 2024.
- ^ Watkins, John B.; Sullivan, Sean D.; Sampsel, Elizabeth; Fullerton, D S "Pete"; Graff, Jennifer S.; Fry, Richard N.; Lee, Jeff; Tam, Iris M.; Avery, Steven G. (June 2020). "Evolution of the AMCP Format for Formulary Submissions". Journal of Managed Care Specialty Pharmacy. 26 (6): 696-700. doi:10.18553/jmcp.2020.26.6.696. PMID 32463780.
- ^ Langley, Paul C.; Sullivan, Sean D. (1996). "Pharmacoeconomic evaluations: guidelines for drug purchasers". Am J Manag Care. 2 (6): 671-677. doi:10.18553/jmcp.2020.26.6.689. PMID 32463775.
- ^ Academy of Managed Care Pharmacy. "AMCP Format for Formulary Submissions". Academy of Managed Care Pharmacy. Retrieved 19 December 2024.
- ^ Sullivan, Sean D.; Lyles, Alan; Luce, Bryan; Grigar, Joseph (July 2001). "AMCP Guidance for Submission of Clinical and Economic Evaluation Data to Support Formulary Listing in U.S. Health Plans and Pharmacy Benefits Management Organizations". Journal of Managed Care Pharmacy. 7 (4): 272-282. doi:10.18553/jmcp.2001.7.4.272.
- ^ National Academy of Medicine. "National Academy of Medicine Elects 100 New Members".
- ^ Hydery, Tasmina; Reddy, Vimal (2024). "A primer on formulary structures and strategies". J Manag Care Spec Pharm. 30 (2): 206–210. doi:10.18553/jmcp.2024.30.2.206. PMID 38308624.
- ^ Sullivan, Sean D.; Yeung, Kai; Vogeler, Carol; Murphy, Chad O.; Danielson, Dan; Veenstra, David L.; Garrison, Louis P.; Burke, Wylie; Watkins, John B. (2015). "Design, Implementation, and First-Year Outcomes of a Value-Based Drug Formulary". J Manag Care Spec Pharm. 21 (4): 269–75. doi:10.18553/jmcp.2015.21.4.269. PMID 25803760.
- ^ Yeung, Kai; Basu, Anirban; Hansen, Ryan N.; Watkins, John B.; Sullivan, Sean D. (2017). "Impact of a Value-Based Formulary on Medication Utilization, Health Services Utilization, and Expenditures". Med Care. 55 (2): 191–198. doi:10.1097/MLR.0000000000000630. PMID 27579915.
- ^ Yeung, Kai; Cruz, Maricela; Tsiao, Emily; Watkins, John B.; Sullivan, Sean D. (2024). "Drug use and spending under a formulary informed by cost-effectiveness". J Manag Care Spec Pharm. 29 (11): 1175–1183. doi:10.18553/jmcp.2023.29.11.1175. PMID 37889867.